Safety, Pharmacokinetics and Preliminary Efficacy of IL4-R α Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
ConclusionsAK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD.Clinical Trial RegistrationClinicalTrials.gov identification number: NCT04256174. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
Correction to: Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 3, 2023 Category: Dermatology Source Type: research
Correction to: Real-World Treatment Patterns in Patients with Vitiligo in the United States
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 2, 2023 Category: Dermatology Source Type: research
